Listar por autor "Subbiah, Vivek"
Mostrando ítems 1-4 de 4
-
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Subbiah, Vivek; Braña Garcia, Irene; Longhi, Alessandra; Boni, Valentina; Delord, Jean-Pierre; Awada, Ahmad (American Association for Cancer Research, 2022-07-01) -
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
Fudio, Salvador; Tabernero Caturla, Josep; Subbiah, Vivek; Chawla, Sant P.; Moreno, Victor; Longo-Muñoz, Federico (Springer, 2021-01) -
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Subbiah, Vivek; Cassier, Phillippe A.; Siena , Salvatore; Garralda Cabanas, Elena; Paz-Ares, Luis; Garrido, Pilar (Nature Research, 2022-08) -
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, Frank; Curigliano, Giuseppe; Thomas, M.; Subbiah, Vivek; Baik, Christina; Tan, Daniel S. W.; Garralda Cabanas, Elena (Elsevier, 2022-11)